Investigating the role of COL1A1 and FN1 gene expression in cisplatin-resistant ovarian cancer

Ovarian cancer (OC) is a fatal malignancy that has been attributed majorly to the emergence of chemoresistance. Cisplatin is a first-line treatment, but its resistance is one of the main clinical challenges. This study examined how two extracellular matrix (ECM) genes; COL1A1 and FN1 play a role in cisplatin-resistant ovarian cancer. We examined gene expression in the A2780 human ovarian carcinoma cell line and its cisplatin resistant counterpart (A2780-R) through quantitative real-time PCR (qRT-PCR). The results of our study demonstrated that the genes were significantly downregulated in the resistant cells. The reduced expression of FN1 and COL1A1 observed in cisplatin-resistant ovarian cancer cells may indicate a cell-specific adaptive mechanism, potentially shaped by differences in cisplatin dosage or exposure patterns that modify extracellular-matrix gene regulation. Because both the amount and scheduling of cisplatin administration influence cellular responses, variations in dosing regimens may affect how resistance emerges and ultimately shape therapeutic outcomes. It shows that there is a previously underestimated resistance mechanism that should be examined.